Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

24 mai 2016 12h25 HE | Source: AIM ImmunoTech Inc.

UPDATE -- Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

PHILADELPHIA, May 24, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...
23 mai 2016 08h30 HE | Source: AIM ImmunoTech Inc.

Hemispherx Amends and Restates Agreement with myTomorrows for the Early Access Program for Rintatolimod in Europe

PHILADELPHIA, May 23, 2016 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced today that it has executed an amended and restated agreement with Impatients, N.V., a Netherlands based...